Vireo Growth's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Vireo Growth's ROA in the second quarter of 2026?
Vireo Growth Inc. recorded a cumulative net loss of $-67 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -7.3%.

However, within the Healthcare sector Vireo Growth Inc. achieved the highest return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3211, from total ROA ranking in the first quarter of 2026 at 3794.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	91.4 %	235.25 %	306.1 %	692.33 %	690.3 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-67	-82	-68	-63	-42
Return On Assets (TTM)	-7.3 %	-10.66 %	-11.25 %	-13.99 %	-13.79 %
VREOF's Total Ranking	# 3211	# 3794	# 3377	# 3364	# 3387
Total Assets (TTM) in million	1,262	929	806	679	659
Seq. Total Assets Change	35.87 %	15.3 %	18.66 %	2.97 %	137.99 %
Seq. Net Income Change	-	-	-	-	-

VREOF's 5 Years Annual ROA >> Back to VREOF Management Effectiveness >> Compare VREOF ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	#
Sector	#
Overall	# 0

Return On Assets Statistics
High	Average	Low
-7.25 %	-17.35 %	-30.64 %
(Jun 30 2026)		(Mar 31 2022)

Financial Statements
Vireo Growth's Assets	$ 1,262 million	VREOF's Balance sheet
Vireo Growth's Income	$ 0 million	Quarterly VREOF's Income Statement
VREOF's Income by Division		See VREOF's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2020) FY 2021
Y / Y Total Assets Change	128.57 %	82.7 %	-32.16 %	68.12 %	-
Total Assets in million	453	198	109	160	95
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-68	-28	-26	-42	-23
Annual Return On Assets	-15.02 %	-14.12 %	-23.53 %	-26.53 %	-24.1 %

VREOF's 5 Years Annual ROA >> Back to VREOF Management Effectiveness >> Compare VREOF ROA to its Competitors

More Return On Assets Ratios
VREOF's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
VREOF's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for VREOF's Competitors
Subscribers only: Roa for Vireo Growth's Suppliers
Subscribers only: Return On Assets for VREOF's Customers

You may also want to know
VREOF's Roi	VREOF's Inventory Turnover Ratio	VREOF's Growth Rates	VREOF's Dividend Comparisons
	VREOF's Profitability Ratios	VREOF's Asset Turnover Ratio	VREOF's Dividend Growth
VREOF's Roe	VREOF's Valuation Ratios	VREOF's Financial Strength Ratios	VREOF's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-08-17T17:19:27+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.